BLOG
New DEA Guidance On Quantitative Thresholds
Guidance On Quantitative Thresholds | by: Deneen Fumich, RPh | Article Posted: January 20, 2023 | As the Pharmaceutical Supply Chain continues to digest the Injunctive Relief requirements for the Big 3 Wholesalers, questions have been posed by industry to both the...
Recent Articles
Dogfight for Disruption: Drone Drug Delivery
It’s a matter of time until drone delivery of prescription drugs becomes the norm.
PillPack’s Recent Public Battles
Amazon’s PillPack is fighting battles everyday, as it tries to wrest revenue, profit and valuation from deeply entrenched players in this (mostly) zero-sum game. However, as with everything else: you win some and you lose some. Below is a recount on some of the recent moves over the summer!
High-Reimbursement Drugs – Why?
High reimbursement drug products have been an underground current in the practice of pharmacy for over a decade. However, only in the past 5 or 10 years has this part of the industry expanded enough to bring Federal attention.
Iowa Board of Pharmacy Approves NCDQS QAS Accreditation as Part of Waiver to VAWD Requirement
In 2018, legislation was passed in Iowa that required a company to have VAWD Accreditation as a prerequisite to being awarded wholesale drug distribution licensing, in line with three other states.
Puerto Rico’s Regulation of the Drug Supply Chain: Past, Present and Future
Puerto Rico became a U.S. territory over 100 years ago after the conclusion of the Spanish-American War. As a territory that is still citing laws passed as early as 1912 to regulate the pharmaceutical supply chain, there are many nuances to ensuring compliance when doing business on the island.
Market Viability of Canadian Importation
Drug Importation has been a longtime coming. The law that developed a framework for importation of prescription drugs originally became effective in January 2012 but over 7 years later, not much has been done. In September 2018, Vermont passed a bill SB175 (read our article on it here) which had specific challenges: DSCSA compliance, Diversion, Manufacturer tactics, Politics, Quality concerns, Relabeling costs, just to name a few.
